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Sumaru We established a panel of 17 xenografts from primary human breast carcinomas. We examined
which characteristics of the original tumours and the xenografts facilitate growth in animals. Tumours
expressing medium or strong immunoreactivity for p53 protein had significantly (P<0.05) higher incidence
(920%4 of in vivo tumour take than those showing weak or negative immunoreactivity (9.10%). No such
association was observed between either c-erbB-2 or epidermal growth factor receptor (EGFR) expression in
the original tumours and their in vivo tumour take. Following subcutaneous (s.c.) transplantation of original
breast tumours or established xenografts. 7 17 tumours showed metastatic disease spread to distant sites
(mainly lungs). This study suggests that selective growth of highly aggressive tumours occurs during in vivo
propagation of malignant tumours. and these tumours will be of particular interest in evaluating various
chemotherapeutic agents for breast cancer management.
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Human tumour xenografts established in athymic mice pro-
vide important experimental material for cancer research.
For long-term experiments or studies in which repetitive
analysis is required. xenografts developed from human
tumours can expand the resources available to researchers.
However, only a few tumour types grow in animals
(Giovanella and Fogh. 1985). For human breast carcinomas,
tumour take is generally low, about 6-15% (Rae-Venter and
Reid. 1980: Fogh et al.. 1982; Giovanella et al., 1989, 1991).
Recently. we achieved significant success in establishing
human breast tumour xenograft lines in athymic mice (Mehta
et al.. 1993). Enzyme-dispersed tumours were mixed with
Matnrgel (a mixture of basement membrane components),
then injected subcutaneously (s.c.) into athymic mice. Mat-
rigel use not only increased tumour take, but also enhanced
tumour growth and facilitated distant metastasis (Mehta et
al., 1993).
The initial establishment and subsequent growth of a solid
tumour results from successful interaction between tumour
cell basement membranes and surrounding stromal com-
ponents. Expansion and metastasis of primary tumours
depend on angiogenesis (Gimbrone et al.. 1972; Furcht.
1986). Basement membrane components, especially laminin
and various growth factors, are directly involved in tumour
angiogenesis (Folkman. 1972: Sakamoto et al.. 1991:
Yamamura et al., 1993).
Matrigel is a mixture of various components. containing
mainly laminin (56%), collagen IV (31%). heparan sulphate
(5%) and entactin (8%). It also contains various growth
factors generally present in basement membrane (Sabiston et
al., 1985; Passaniti et al., 1992). Matrigel and laminin
enhance the tumour take and promote growth of various
human tumour types (Pretlow et al.. 1991; Yamamura et al.,
1993). Laminin also promotes tumour cell adhesion, cell
migration and invasion and metastasis (Barsky et al., 1984;
Terranova et al.. 1984: Fridman et al., 1990. 1991; Kleinman
et al., 1991). However, in addition to factors associated with
basement membrane and stroma, the original tumours' char-
acteristics associated with tumour aggressiveness may also
modulate the in vivo tumour take in experimental animals.
Overexpression amplification or mutation of various onco-
genes. especially c-erbB-2 and p53. not only alters expression
of various receptors binding to basement membrane com-
ponents, but also enhances metastatic potential (Liotta et al.,
1986; Taylor et al.. 1992; Yu et al., 1992; D'Souza et al.,
1993).
In the present study, we characterised the original patients'
breast tumours, especially their expression of c-erbB-2, p53
and EGFR, and examined which of these factors favour their
xenograft development and their growth in athymic mice
when tumours were co-injected with Matnrgel.
Materials and methods
Three- to four-week-old female Balb c athymic mice were
obtained from the Frederick Cancer Research Facility,
Bethesda, MD, USA. Animals were maintained in a
pathogen-free environment.
Human breast tissues
Human breast tumour tissues were obtained from women
undergoing mastectomy or lumpectomy for a confirmed diag-
nosis of breast carcinoma. After processing for his-
topathological diagnosis the tumour tissues were immediately
transported on ice to the laboratory for steroid receptor
analysis. Tumour tissue (approximately 0.8 g) was reserved
for receptor analysis; any remaining thereafter was used for
experimental studies. Clinical information was obtained
regarding patients' age at diagnosis, number of positive axil-
lary lymph nodes and steroid receptor content of tumours;
this information was entered into our departmental computer
system. All tumours used in the present study were primary
breast carcinoma.
Establishment ofbreast carcinoma xenografts in athvmic mice
Human breaAt carcinoma xenografts were established from
fresh tumour tissues from patients with a confirmed diagnosis
of breast cancer. The tumour tissues were minced into small
pieces, one of which was processed for histology, and the
remaining tissue was digested overnight at room temperature
in a cocktail of enzymes, namely 0.1% collagenase type IV,
0.01% hyaluronidase and 0.02% deoxyribonuclease (Sigma,
St Louis, MO, USA), contained in Hanks' balanced salt
solution (HBSS; Biologos. Naperville, IL. USA). The result-
ing cell suspension was centrifuged, and 0.05-0.10 g of tissue
pellet was resuspended in HBSS, mixed with (1:1 volume)
Matrigel (Collaborative Biomedical Products, Becton Dickin-
son Labware, Bedford, MA. USA) and then injected s.c. into
Correspondence: RR Mehta
Receised 6 Januar'- 1995: resised 5 June 1995. accepted 27 June
1995.athymic mice. None of these animals received exogenous
hormonal supplement, regardless of the steroid receptor
status of the original patients' tumours.
Tumour grow th in animals
All animals, injected with either original patients' tumour or
athymic mice xenograft. were examined twice weekly for
development of palpable tumour at the site of injection or
other subcutaneous sites. The tumour volume was deter-
mined using vernier calipers. Tumour doubling time was
calculated as the number of days required for the tumour to
grow from x volume to 2x volume. The tumour latency
period is the time (days) required for the tumour to show
apparent sustained increase in volume from the initial volume
of the injected suspension or xenograft. The experiments
were performed in groups of 3-4 animals. The tumour doub-
ling times represent the mean values obtained in three or four
animals at the same in vivo passage.
Histological studies
At the termination of experiments. animals were sacrificed
and tumours were excised and aseptically cut into small
pieces. For histological and immunohistochemical studies,
tissues were fixed in 10% buffered formalin. The animals
were autopsied and examined for any evident tumour metas-
tasis at distant visceral sites. The visceral organ(s) with
suspected metastases were processed for microscopic
examinations. The original patients' tumours were also fixed
in 10% buffered formalin for immunohistochemical studies.
Immunohistochemical studies
Immunohistochemical tests for p53, c-erbB-2 and EGFR
were performed in both original patients' tumours and their
nude mouse xenografts. using the standard assay (Mehta et
al., 1992) with minor modifications. In brief, 4- to 5-nm-thick
formalin-fixed tissue sections were mounted on polylysine-
coated slides and processed for immunohistochemical studies.
Tissues were deparaffinised in xylene, dehydrated in a senres
of alcohol baths and washed with phosphate-buffered saline
(PBS). Tissue sections were microwaved at 80% power for
15 min, either in 6 M urea (for p53) or in 0.01 M citrate buffer
(for c-erbB-2 and EGFR) (Cattoretti et al., 1993). After
30 min. tissues were transferred to PBS and extensively
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washed with PBS. Non-specific reaction was blocked by
incubating tissues for 15 min with 5% non-fat dry milk. The
sections were incubated overnight at 4'C with primary
c-erbB-2 antibody (Ab-3. 1:20 dilution), p53 antibody (Ab-3,
1:20 dilution; Ab-6. 1:10 dilution) or EGFR antibody (Ab-4,
1:20 dilution). All antibodies were obtained from Oncogene
Science (New York. NY. USA). Tissues incubated with
mouse IgG (5 jigml-') served as experimental control. Fol-
lowing incubation, sections were washed in PBS and
incubated with biotinylated anti-rabbit anti-mouse link
antibody and peroxidative conjugated streptavidin (DAKO,
Carpinteria. CA, USA). Immunohistochemical reaction was
visualised using AEC (3-amino-9-ethylcarbazole) as substrate.
Tissues were counterstained with haematoxylin and mounted
in permount.
Only nuclear staining for p53 protein or membrane stain-
ing for c-erbB-2 and EGFR were considered as positive. The
intensity of staining was scored as '-' ifchromogen reaction
was not evident, '±' if chromogen reaction was slightly
higher than that observed in the respective control. These
tissues were classified as negative. Tumours showing a
definite difference in staining pattern compared with their
respective assay controls were considered positive, and scored
as medium (+ +) or strong (+ + +. + + + +) immunoreac-
tivity.
Statisticalanalysis
Results are expressed as mean ± s.e. Statistically significant
differences between group means were determined by ANOVA (analysis of variance test). Differences in the
incidence (%) between groups were determined by chi-square
analysis. A value of P<0.05 was considered significant.
Results
Characteristics ofhuman breast cancer
Twenty-eight (n = 28) primary breast carcinomas from
women were obtained at the time of either lumpectomy or
mastectomy. None of these patients had any detectable
evidence of metastasis. Tumours were enzymatically digested,
mixed with Matrigel and injected s.c. into athymic mice. All
tumours used contained malignant cells. as evident from
histological examination of adjacent tissue. Of these 28




Total tumour take Incidence oftumour
(n) (n) development (%
Variable menopausal status
Premenopausal 12 28 8 12 66.6
Post-menopausal 16 28 9 16 52.9
Positive lymph nodes
1-9 Positive nodes 5 28 4 5 80.0
0 Positive nodes 22 28 12 22 54.5
Unknown 1 28 1 1 100.0
Steroid receptors
ER+ 12 28 6 12 50.0
ER- 15 28 10 15 66.6
Not known 1 28 1 1 100.0
p53 staining
Weak negative (p53-negative) 11 24 1 11 9.1**
Medium strong (p53-positive) 13 24 12 13 92.3**
c-erbB-2a
Weak negative (c-erbB-2-negative) 8 24 4 8 50.0
Medium strong (c-erbB-2-positive) 16 24 10 16 62.5
EGFRa
Weak negative (EGFR-negative) 19 24 9 19 45.0
Medium strong (EGFR-positive) 5 24 5 5 100.0**
Total. 28 patient tumours. aOf 28 tumours, 24 were available for immunocytochemistry. **Significant (P<0.05) difference between groups by chi-square test.Mutarnt p53 and c-erbB-2 in breast cancer tumour tae
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tumours. 17 (60.700) developed palpable xenografts at the
site of injection. All 17 xenografts retained the same his-
tological characteristics as the primary tumour from which
they were derived. Table I shows the characteristics of
original patients' tumours used for this study. Twelve of 28
tumours (42.900) were from premenopausal women between
24 and 47 years of age. Of these 12 tumours. 8 (66.7%o) had
positive tumour take in animals. Sixteen tumours were from
post-menopausal women. and mnne (56.3%) of these dev-
eloped xenografts. Twenty-two of 28 tumours were obtained
from women with no evidence of metastatic disease spread to
ipsilateral lymph nodes (node negative), and 12 of these 22
had positive take in mice. Five of 28 had positive lymph
node status (1-9 positive nodes). Four of these (80%) suc-
cessfully developed as xenografts. Six of 12 (50%) oestrogen
receptor (ER)-positive (ER') and 10 15 (66%) ER-negative
(ER-) tumours produced tumours in animals.
Expression of mutant type tumour-suppressor p53 protein.
membrane-associated c-erbB-2 protein and EGFR protein
was studied immunohistochemically in formalin-fixed tissue
sections. Tumours were available from 24 of 28 specimens.
Immunohistochemical studies for p53 protein were performed
using two different antibodies: Ab-6. which is directed
against both wild-type and mutant human p53 protein, and
Ab-3. which is directed solely against the mutant type of p53
but shows cross-reactivity in various species. including
humans and mice. Thus. comparing results obtained using
these two different antibodies allowed us to detect the
presence of mutant-type p53 in both clinical specimens and
their xenografts established in athymic mice. Detection of
nuclear p53 by both antibodies necessitated unmasking of
antigens in tissues, probably resulting from formalin fixation.
Tissue sections were microwaved in 6M urea for 15 min
before immunostaining. Immunohistochemical studies of
c-erbB-2. a membrane-associated protein. were performed in
24 original patients' tumours.
The intensity of immunostaining showing nuclear staining
varied from tumour to tumour. In 11 24 (45.9%) tumours.
undetectable or very weak p53 staining was observed. Only
one of these 11 tumours (9.1%) developed as xenografts in
animals. On the other hand. 13 24 (54.2%) tumours had
medium to strong immunoreactivity with the p53 antibody:
12 of these 13 (92.3%) tumours had positive tumour take.
Tumour take was significantly (P<0.05) higher in tumours
with high p53 protein than those with negative or weak
reaction. In general. the presence or absence of p53 staining
did not appear to be affected by steroid receptor contents in
the tumour. histopathology of the tumour. extent of disease
spread in patients or patient's age at diagnosis.
For c-erbB-2. 8 24 (33.3°0o) tumours had negative to weak
staining, and 16 24 (66.6%) showed medium to strong stain-
ing. In viio tumour take was not significantly different
between primary tumours with high expression of c-erbB-2
protein and those with undetectable or weak c-erbB-2 expres-
sion (62.5% vs 50.0%). The presence ofmembrane-associated
EGFR was detected in five of 24 (20.8%) tumours, all five of
which had positive tumour take in experimental animals
(Table I). On the other hand, nine of 19 (47.4%) EGFR-
negative tumours also grew in mice.
These 17 xenografts were originated from a histopatho-
logically diverse group of breast carcinomas (e.g intraductal
carcinoma, infiltrating ductal carcinoma, medullary type.
lobular type, mucin secreting, papillary carcinoma).
Growth characteristics of xenografts in mice
Initially. following s.c. injection of enzymatically dispersed
tumour cells in athymic mice, palpable xenografts developed
at the injection site within 17-145 days. These xenografts
were excised and retransplanted into animals without Mat-
rigel. In the first in vivo passage. the tumour latency period
was shortened for all tumours, ranging between 4 and 22
days. Tumour doubling time at the exponential growth phase
varied between 2 and 28 days. Tumour doubling time did not
differ significantly for xenografts originated from different
histopathological subtypes. for ER+ and ER- tumours or for
tumours showing different immunoreactivitv to p53. c-erbB-2
or EGFR.
Light-microscopic examination of the original xenograft
tumours revealed that these xenografts were histopatho-
logicallv identical to the original patients' tumours. except
that most of these tumours were mainly composed of
epithelial cells. with minimal presence of stromal components
surrounding the tumour cells.
Immunohistochemical studies for p53. c-erbB-2. and
EGFR were performed in xenografts bv the methods des-
cribed previously for the patients' tumours. In general. the
results obtained in xenografts agreed with those observed in
their respective patients' tumours (Figure 1). In 13 of 17
(76.5%) xenografts. nuclear staining specific for p53 protein
was observed. Similarlv. 13 of 17 (76.5%) tumours showed
overexpression of c-erbB-2 protein. In contrast to p53 and
c-erbB-2. for EGFR. only one of 17 (5.9%) xenografts had
medium staining (localised to cell membranes). although its
respective tumour had weak immunostaining. However. five
xenografts originated from tumours with medium EGFR
staining had no detectable immunoreactivitv for EGFR.
Metastasis to distant organs was frequently (33-66%)
observed after s.c. transplantation into athymic mice of
original patients' tumours or established xenografts. The
incidence of metastasis increased during serial transplantation
of xenografts (data not shown). Six of 17 (35.3%) xenografts
showed metastatic lesions at various in vivo passaging in the
lung. Distant metastasis was confirmed by histological
examination of suspected lesions. The incidence of metastases
was higher in xenografts originating from tumours of
premenopausal women (5 8. 62.5'o) than in those from post-
menopausal woman (2 9. 22.2 0o).
Discussion
We achieved significant success in establishing human breast
carcinoma xenografts in athvrmic mice using Matrigel. a mix-
ture of reconstituted basement membrane. Seventeen of 28
breast tumours transplanted s.c. developed continuously
transplantable xenograft lines. The incidence of breast
tumour take in our study is significantly higher than that
reported by other investigators (generally 6-15%) (Rae-
Venter and Reid. 1980: Fogh et al.. 1982; Giovanella et al..
1989. 1991).
For continued growth of solid malignant tumour. induc-
tion of angiogenesis is essential (Gimbrone et al.. 1972). In
the absence of neovascularisation, tumour nodules fail to
grow larger than a few millimetres in diameter (Gimbrone et
al.. 1972). Recently, laminin and various growth factors-
especially transforming growth factor beta (TGF-P) and basic
fibroblast growth factor (BFGF) have been shown to play an
important role in angiogenesis (Sakamoto et al.. 1991:
Yamamura et al.. 1993). Cys-Asp-Pro-Gly-Tyr-Ile-Gly-Ser-
Arg-NH2 (CDPGYIGSR-NH2). a laminin-denrved polypep-
tide containing an active site for cell binding, inhibited both
angiogenesis and solid tumour growth (Sakamoto et al..
1991; Yamamura et al.. 1993). In vivo. CDPGYIGSR-NH'
inhibited the growth of subcutaneously transplanted solid
sarcoma tumour and Lewis lung carcinoma (Yamamura et
al.. 1993). The effect of this peptide in these animals was not
direct. but was mediated through its angiogenesis inhibitory
influence (Yamamura et al.. 1993). In the study reported
herein, significantly high tumour take of human breast car-
cinomas, irrespective of their original histopathological sub-
types, may partly result from induction of angiogenesis by
components present in Matrigel.
In addition to higher tumour take. we also observed fre-
quent (7 17. 41.2%) distant metastasis following s.c. trans-
plantation of xenografts into animals. Most of these tumours
were from premenopausal women and expressed high levels
of p53 and c-erbB-2 proteins.
Possibly. during serial in vivo transplantation of tumours.
only selective highly aggressive tumours grow successfully.Mutant p53 and c-erbB-2 in breast cancer tumour take









Figure I Immunohistochemical studies for c-erbB-2 and p53 protein in patient's onrginal tumour (UISO-NMT-BCA-15) and
xenograft tumours. (a) Haematoxxlin and eosin (H and E) staining of patient's tumour. (b) Nude mouse xenograft. H and E
staining. (c) p53 staining in patient-s tumour. (d) p53 staining in xenograft tumour. (e) c-erbB-2 staining in patient's tumour. (f)
c-erbB-2 staining in xenograft tumour.
This hypothesis is supported by histopathological and
immunohistochemical characteristics of original and xeno-
graft tumours observed in the present study.
Histopathologically, most breast tumours used in the pres-
ent study contained patches or clusters of malignant cells
embedded in stromal tissues: however, xenografts developed
from these tumours were wholly epithelial and contained a
minimal amount of stromal elements. Thus, even though
tumour cells in xenografts show histological similarity to the
patients' original tumours. the relative distribution of cellular
components in the tumour is identical to metastatic tumours
observed in humans (Giovanella et al., 1991).
In a clinical setting, overexpression of c-erbB-2. p53 or
EGFR in tumours is associated with disease aggressiveness
(Thor et al.. 1989; Kallioniemi et al.. 1991; Gasparini et al..
1994). We examined immunohistochemically the expression
of these prognostic markers in 24 tumours regardless of their
tumour take in mice. Twelve of 24 (50.0%) showed
medium-strong immunoreactivity to p53; 8 24 (33.3%) had
c-erbB-2 overexpression; and 5 29 (17.2%) showed EGFR
immunoreactivity. These results are similar to those recently
reported for clinical specimens (Wolman et al.. 1991: Kopp et
al.. 1993: Silvestrini et al.. 1993). Tumour take was
significantly higher in tumours expressing mutant p53 protein
(92.3%) than in those showing weak or no p53 expression
(9.1%). Recently. Hurst et al. (1993) established a human
breast tumour xenograft line with metastatic potential which
was also positive for p53 protein, but negative for the
c-erbB-2 oncogene. In the study presented here. 62.5% of
tumours with overexpressed c-erbB-2 protein expression and
50% of c-erbB-2-positive tumours grew as xenografts.
Giovanella et al. (1991) evaluated 11 tumours that developed
xenografts in nude mice: seven of these 11 (64%) showed
evidence of c-erbB-2 gene amplification. The incidence of
c-erbB-2-positive tumours obtained in our studv is similar to
that reported by Giovanella et al. (1991). However. in the
latter study. only tumours with positive in vivo growth were
examined. Results obtained in the present study suggest that.
under the experimental conditions used for in vivo propaga-
tion. growth of highly aggressive tumours (especially those
expressing mutant p53 protein) occurs.
Tumour latency period and growth rates of xenografts. as
measured by tumour doubling time. were not influenced by
expression of p53. c-erbB-2. or EGFR in patients' tumours
or in xenografts. This is probably because each inoculation
of tumour contained a varying proportion of malignant cells.
Thus, even though most tumours showing successful growth
in mice are highly aggressive, no association was observed
between initial in vivo growth rate and relative expression of
the markers studied.
In general. xenografts developed in mice preserved the
expression of p53 and c-erbB-2 and the histopathological
characteristics of their original tumours. In contrast. EGFR
expression differed in tumours and their respective xeno-
grafts. Perhaps some original phenotype characteristics of
cells are altered during the propagation of tumours in mice.
Such alteration may be due to superficial interference of
host-associated factors with EGFR in the tumour or may be
a true alteration dunrng the process of xenograft establish-
ment.
In conclusion, these human breast carcinomas grown in
vivo in experimental animals will provide suitable material for
experiments evaluating how well vanrous chemotherapeutic
agents control growth ofhighly aggressive breast cancer cells.
Abbreviatioa
EGFR. epidermal growth factor receptor: PBS. phosphate-buffered
saline; AEC. 3-amino-9-ethylcarbazole; s.e. standard error:
ANOVA. analysis of variance test: ER. oestrogen receptor: TGF-P.
transforming growth factor-P, BFGF. basic fibroblast growth factor;
CDPGYIGSR-NH-. Cys-Asp-Pro-Gly-TvT-Ile-Glv-Ser-Arg-NH2
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